Article Text

Download PDFPDF
Long-acting risperidone increases medication costs and does not improve outcomes in unstable schizophrenia

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


Question: What is the effect of long-acting injectable (LAI) risperidone on healthcare costs and outcomes in people with unstable schizophrenia or schizoaffective disorder?

Patients: In total, 369 adult patients who had Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV) diagnosis of schizophrenia or schizoaffective disorder and were at risk of psychiatric hospitalisation (those hospitalised in the previous 2 years and those whose use of mental health services to prevent relapse had been increasing).

Setting: Nineteen Veterans Affairs medical centres, USA; 2006–2008.

Intervention: LAI risperidone 25–50 mg every 2 weeks or psychiatrist's choice of oral antipsychotic medication (control).

Outcomes: Utilisation of health services and medication (acute medical/surgical hospital stays, acute psychiatry hospital stays, residential and other inpatient hospitalisation and outpatient visits); healthcare cost (inpatient stays, outpatient visits and outpatient medications; analysed from the perspective of the US Medicaid healthcare sponsor); symptoms of schizophrenia using Positive and Negative Syndrome Scale and health-related quality of life using Quality of Well-Being (QWB) Scale.

Patient follow-up: Not reported.


Design: Randomised controlled trial.

Allocation: Not reported.

Blinding: Single blind (assessors blinded).

Follow-up period: Maximum …

View Full Text


  • Sources of funding: The Veterans Affairs Cooperative Studies Program. An unrestricted grant and the study drug (long acting risperidone) were provided by Ortho-McNeil Janssen Scientific Affairs, LLC.